We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-angiotensin system inhibitors.
- Authors
Qian Chen Yong; Thomas, Candice M.; Seqqat, Rachid; Chandel, Niketa; Baker, Kenneth M.; Kumar, Rajesh
- Abstract
Background Diabetes-induced organ damage is significantly associated with the activation of the reninangiotensin system (RAS). Recently, several studies have demonstrated a change in the RAS from an extracellular to an intracellular system, in several cell types, in response to high ambient glucose levels. In cardiac myocytes, intracellular angiotensin (ANG) II synthesis and actions are ACE and AT1 independent, respectively. However, a role of this system in diabetes-induced organ damage is not clear. Methods To determine a role of the intracellular ANG II in diabetic cardiomyopathy, we induced diabetes using streptozotocin in AT1a receptor deficient (AT1a-KO) mice to exclude any effects of extracellular ANG II. Further, diabetic animals were treated with a renin inhibitor aliskiren, an ACE inhibitor benazeprilat, and an AT1 receptor blocker valsartan. Results AT1a-KO mice developed significant diastolic and systolic dysfunction following 10 wks of diabetes, as determined by echocardiography. All three drugs prevented the development of cardiac dysfunction in these animals, without affecting blood pressure or glucose levels. A significant down regulation of components of the kallikrein-kinin system (KKS) was observed in diabetic animals, which was largely prevented by benazeprilat and valsartan, while aliskiren normalized kininogen expression. Conclusions These data indicated that the AT1a receptor, thus extracellular ANG II, are not required for the development of diabetic cardiomyopathy. The KKS might contribute to the beneficial effects of benazeprilat and valsartan in diabetic cardiomyopathy. A role of intracellular ANG II is suggested by the inhibitory effects of aliskiren, which needs confirmation in future studies.
- Subjects
DIABETES complications; ORGANS (Anatomy); ANGIOTENSIN receptors; BLOOD sugar; BLOOD pressure; HEART failure; LABORATORY mice; WOUNDS &; injuries
- Publication
Cardiovascular Diabetology, 2013, Vol 12, Issue 1, p1
- ISSN
1475-2840
- Publication type
Article
- DOI
10.1186/1475-2840-12-169